The European Federation of the Organizations of Medical Physics (EFOMP), through its Special Interest Group For Radionuclide Internal Dosimetry (SIG_FRID), after the great success of the 1st edition in 2023, organized the 2nd Symposium on Molecular Radiotherapy Dosimetry in Athens, Greece from 13th to 15th November 2025. This congress, subtitled “The future of theragnostics”, was…
Read more
FLUKA calculations were used to estimate the production rate of Ag-111 and other medical radionuclides at SPES. A detailed explanation is presented in a dedicated page. These calculations were published in the following papers: Andrighetto, A., Tosato, M., Ballan, M. et al. The ISOLPHARM project: ISOL-based production of radionuclides for medical applications. J Radioanal Nucl Chem 322, 73–77…
Read more
After several experimental works, a first theoretical study was recently released by the SPES-ISOLPHARM laser group. The paper, entitled “Laser photo-ionization efficiency of silver-111 for the SPES-ISOLPHARM project”, was published by the journal Applied Radiation and Isotopes (https://doi.org/10.1016/j.apradiso.2025.112143) and investigates, through the quantum density matrix formalism, the optimization of the laser parameters affecting the photo-ionization…
Read more
Two new papers were published by the ISOLPHARM collaboration in July 2025. Both articles belong to the WP4 activities of the ADMIRAL experiment, dealing with radiobiology and radiation biophysics. The first one, entitled “Monte Carlo dosimetry of silver-111 in simplified cell geometries in the framework of the ISOLPHARM project” and published by the journal Applied…
Read more
The latest achievements of the SPES-ISOLPHARM beamline were presented by Alberto Arzenton at the 16th International Conference on Heavy Ion Accelerator Technology (HIAT25), which took place at the Michigan State University (East Lansing, MI, USA) from 22nd to 27th June 2025. The content of the presentation can be found in the conference proceeding, named The…
Read more
In May 2025 the WP3 of the ADMIRAL experiment performed a characterization test of the gamma camera using Ag-111 produced at LENA, Pavia. For the first time a mouse phantom was employed to simulate the case of an in-vivo experiment. Big thanks to the LENA personnel!
We are proud to announce that the ISOLPHARM group will arrange a thematic workshop entitled ISOL technique for the production of medical radionuclides at the FisMat 2025 conference, which will take place in Venice from 7th to 11th July. Abstract Nuclear medicine is currently a field of increasing importance in the fight against cancer. The…
Read more
On December 12th, the ISOLPHARM 2024 annual meeting took place at the Legnaro National Laboratories of INFN. The Work Packages of the ADMIRAL and ISOLPHARM_CORE experiments showed their latest results according to the scheduled milestones, while the new SPES_MED experiment was kicked off. All presentations are available on the event’s Indico page. Thank you to…
Read more
The 3D scaffold bioprinting experiments for the ISOLPHARM project started at the beginning of 2024 with some geometry printing tests, where GelMa was cured under a DLP homemade printer with the main task of testing the printing resolution of the instrument. At the end of October the first test where the ink was a mixture…
Read more
In October 2024, the ISOLPHARM collaboration successfully performed the first clonogenic survival evaluation using silver-111 on cancer cells. In particular, the UMR-106 rat osteosarcoma cell line was tested. This result represents a first important experimental milestone reached by the ISOLPHARM radiobiology community, which includes groups from the Universities of Pavia (with the LENA facility), Padova,…
Read more
